Core Viewpoint - The stock of InnoCare Pharma (09606) has risen over 12%, currently trading at 332.2 HKD with a transaction volume of 321 million HKD, driven by positive expectations regarding its clinical pipeline and potential market performance in 2026 [1] Group 1: Clinical Pipeline Expectations - Cathay Securities highlights that InnoCare Pharma has a rich pipeline of catalysts expected in 2026, including final results from global registration clinical trials for HER2 ADC targeting EC and BC indications [1] - Anticipated clinical results for B7H3 ADC, HER2 ADC, and TROP2 ADC in combination with PDL1VEGF dual antibody BNT327 are also on the horizon [1] - Updates on early clinical data for B7H4 ADC and EGFRHER3 ADC, as well as clinical progress for CDH17 ADC, are expected [1] - Initial data disclosure for the early pipeline PDL1*B7H3 ADC is also anticipated [1] Group 2: Sales Forecast and Valuation - Based on the smooth progress of InnoCare's pipeline in 2025, expectations for peak global sales potential for HER2 ADC DB1303, B7H3 ADC DB1311, and HER3 ADC DB1310 have been increased [1] - Using the DCF valuation method, Cathay Securities has raised the target price for InnoCare Pharma to 455.56 HKD while maintaining a buy rating [1]
港股异动 | 映恩生物-B(09606)涨超12% 2026年催化剂丰富 机构上调公司目标价